Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss
NCT05821959
Recruiting
Part A of this trial will evaluate the safety and tolerability of a single unilateral administration of one of two dose levels of AAVAnc80-hOTOF and will evaluate the Akouos delivery device to safely achieve the intended product performance.
Gender:
ALL
Ages:
All
Trial Updated:
06/03/2025
Locations: University of Iowa, Iowa City, Iowa +7 locations
Conditions: Sensorineural Hearing Loss, Bilateral
Register for Updates
A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment
NCT05133531
Recruiting
This study is researching a clinical treatment combination with two experimental drugs called pozelimab and cemdisiran. The study is focused on people with paroxysmal nocturnal hemoglobinuria (PNH). The aim of the study is to see how safe and effective the pozelimab + cemdisiran combination is for people with PNH and how the combination compares with 2 existing treatments: ravulizumab and eculizumab. The pozelimab + cemdisiran combination may be referred to as "study drugs". Ravulizumab and ecu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: The Oncology Institute of Hope & Innovation, Whittier, California +62 locations
Conditions: Paroxysmal Nocturnal Hemoglobinuria
Register for Updates
An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma
NCT05876754
Recruiting
A Phase 3b research study to consolidate the data that ivosidenib is safe and effective in adult patients with previously treated, locally advanced, or metastatic cholangiocarcinoma (CCA). All patients who meet inclusion criteria will be enrolled to receive ivosidenib tablets orally once daily for 28 day cycles, continuing as long as clinical benefit and consent for participation is maintained. There will be a minimum of 6 study visits from screening until the final follow-up, if one cycle of tr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Erebouni MC, Yerevan, Not set +77 locations
Conditions: Cholangiocarcinoma
Register for Updates
TIRCON International NBIA Registry
NCT05522374
Recruiting
TIRCON-reg aims to * continue the provision of a global registry and natural history study for NBIA disorders * harmonize and cover existing national and single site registries * enable participation of countries and single sites that so far have no access to an NBIA registry * join forces in order to recruit sufficient numbers of patients * define the natural history of NBIA disorders * define the most appropriate outcome measures * inform the design and facilitate the conduction of clinical t... Read More
Gender:
ALL
Ages:
All
Trial Updated:
06/02/2025
Locations: Children's Hospital of Eastern Ontario, Division of Neurology, Department of Pediatrics, Ottawa, Not set +8 locations
Conditions: Neurodegeneration With Brain Iron Accumulation (NBIA), Pantothenate Kinase-associated Neurodegeneration (PKAN), Beta-Propeller Protein-Associated Neurodegeneration (BPAN), Mitochondrial Membrane Protein Associated Neurodegeneration (MPAN), Fatty Acid Hydroxylase-associated Neurodegeneration (FAHN), Kufor Rakeb Syndrome, Neuroferritinopathy, Aceruloplasminemia, Woodhouse Sakati Syndrome, COASY Protein-associated Neurodegeneration (CoPAN), PLA2G6-Associated Neurodegeneration (PLAN)
Register for Updates
Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection
NCT05219110
Recruiting
The objective of this study is to determine if early high volume intravenous fluid administration (hyperhydration) may be effective in mitigating or preventing complications of shiga toxin-producing E. coli (STEC) infection in children and adolescents when compared with traditional approaches (conservative fluid management).
Gender:
ALL
Ages:
Between 9 months and 21 years
Trial Updated:
06/02/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +25 locations
Conditions: Shiga Toxin-Producing Escherichia Coli (E. Coli) Infection, Hemolytic-Uremic Syndrome
Register for Updates
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
NCT06592924
Recruiting
This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better or worse than the usual approach for prostate cancer. The usual approach for patients who are not in a study is hormone treatment with Androgen Deprivation Therapy (ADT) and Androgen-Receptor Pathway Inhibitor (ARPI).
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Ottawa Hospital Research Institute, Ottawa, Ontario
Conditions: Prostate Cancer (Adenocarcinoma)
Register for Updates
Oxytocin Maintenance Infusion in Labouring Women Undergoing Cesarean Delivery: an Up-down Sequential Allocation Study
NCT05290129
Recruiting
This study is designed to determine the minimal effective oxytocin maintenance infusion required in labouring women undergoing cesarean delivery to achieve the best effect. Oxytocin is a drug that is routinely used to help the uterus to contract and keep it contracted after delivery. Consequently, it will help to reduce blood loss after delivery. In order to determine the minimal effective dose, the investigators will conduct a dose-finding study. The first patient will receive a set oxytocin in... Read More
Gender:
FEMALE
Ages:
Between 18 years and 50 years
Trial Updated:
06/02/2025
Locations: Mount Sinai Hospital, Toronto, Ontario
Conditions: Postpartum Hemorrhage
Register for Updates
Study on the Effects of Resistant Potato Starch on Gut Bacteria in Healthy Adults
NCT06949631
Recruiting
The goal of this clinical trial is to evaluate how taking Resistant Potato Starch affects the gut microbiota compared to a placebo, in healthy adults. Over a 4-week period, participants will provide stool samples for analysis to detect any changes in gut bacteria. They will also record daily information in a diary about their stool consistency, frequency, digestive symptoms, and overall quality of life.
Gender:
ALL
Ages:
Between 18 years and 69 years
Trial Updated:
05/30/2025
Locations: Apex Trials, Guelph, Ontario/ON
Conditions: Gastrointestinal Microbiota
Register for Updates
Prognosis and Diagnosis of Spasticity in Acute-post Stroke Patients
NCT05179473
Recruiting
Spasticity, or greater muscle resistance, is a major disabling condition following stroke. Recovery of lost motor function in patients with stroke may be affected by spasticity, which most commonly develops in elbow and ankle muscles. However, despite its clinical relevance, the natural development of spasticity over the first 3 months after stroke is not clearly understood. Indeed, common clinical measures of spasticity such as the Modified Ashworth Scale (MAS) do not take into account the neur... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
05/30/2025
Locations: Jewish General Hospital, Montréal, Quebec
Conditions: Stroke, Acute, Stroke, Ischemic, Stroke Hemorrhagic, Spasticity as Sequela of Stroke
Register for Updates
Diagnosing Asthma With Clinically Accessible, Non-invasive, and Efficient Tests: a Child-inclusive Translational Investigation
NCT07011394
Recruiting
Asthma is a common inflammatory respiratory disease affecting 11% of Canadians, but its diagnosis remains challenging, leading to delays in treatment or overtreatment. Spirometry with a reversibility test and bronchial provocation testing (BPT), considered the gold standard, are the reference diagnostic methods. However, access to BPT is limited as it is performed in hospital settings. Type 2 inflammation biomarkers, the fractional exhaled nitric oxide (FeNO) and blood eosinophils (EOS), repres... Read More
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
05/30/2025
Locations: Montreal Children's Hospital, Montreal, Quebec +2 locations
Conditions: Diagnosis, Inflammation, Asthma in Children, Asthma
Register for Updates
An Observational Research Study of the Health of Joints in People With Haemophilia Taking the Medicine Esperoct
NCT05621746
Recruiting
This study will collect information on the long term health of joints in people with haemophilia A who have started treatment with Esperoct within twelve months prior to participation to the study. This study is conducted to look at how joint health of people with haemophilia changes over time when they are receiving the medicine Esperoct. The participants will get Esperoct as prescribed to the participants by the study doctor. The participant's treatment will not be affected by their involvemen... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/30/2025
Locations: Novo Nordisk Investigational Site, Hamilton, Ontario
Conditions: Haemophilia A
Register for Updates
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
NCT05172726
Recruiting
This is an open-label, multi-center, Phase 3 study to evaluate tapinarof cream, 1% in pediatric subjects with plaque psoriasis.
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
05/30/2025
Locations: Clinical Site, Rogers, Arkansas +18 locations
Conditions: Plaque Psoriasis
Register for Updates